<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-Senate" dms-id="A1" public-private="public">
	<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>114 S2023 IS: Prescription Drug Affordability Act of 2015</dc:title>
<dc:publisher>U.S. Senate</dc:publisher>
<dc:date>2015-09-11</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">II</distribution-code>
		<congress>114th CONGRESS</congress><session>1st Session</session>
		<legis-num>S. 2023</legis-num>
		<current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber>
		<action>
			<action-date date="20150911">September 10, 2015</action-date>
			<action-desc><sponsor name-id="S313">Mr. Sanders</sponsor> (for himself and <cosponsor name-id="S332">Mr. Franken</cosponsor>) introduced the following bill; which was read twice and referred to the <committee-name committee-id="SSFI00">Committee on Finance</committee-name></action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To ensure greater affordability of prescription drugs.</official-title>
	</form>
	<legis-body>
		<section id="S1" section-type="section-one"><enum>1.</enum><header>Short title; table of contents</header>
			<subsection id="idC5D033A697AC431A8EABE59DB0325BAE"><enum>(a)</enum><header>Short title</header>
 <text display-inline="yes-display-inline">This Act may be cited as the <quote><short-title>Prescription Drug Affordability Act of 2015</short-title></quote>.</text>
 </subsection><subsection id="idFDC07AE9FBE541C9AA5066DA0356A8D4"><enum>(b)</enum><header>Table of contents</header><text>The table of contents for this Act is as follows:</text><toc><toc-entry idref="S1" level="section">Sec. 1. Short title; table of contents.</toc-entry> <toc-entry idref="id71102C22A3BF4CBF955610D8100F47A3" level="title">TITLE I—Drugs under the Medicare program</toc-entry> <toc-entry idref="HA812C80A6E8442AC999967086D96D6A6" level="section">Sec. 101. Negotiation of lower covered part D drug prices on behalf of Medicare beneficiaries.</toc-entry> <toc-entry idref="id7123C3DFACD9454995947A1A9FCDE761" level="section">Sec. 102. Acceleration of the closing of the Medicare Part D donut hole.</toc-entry> <toc-entry idref="id2A89E3CBB2EC4BDB8EA7E34D4F4902FE" level="title">TITLE II—Prescription drug importation</toc-entry> <toc-entry idref="id94E3F8BBCD35451EA2F2FF4AC3733E9F" level="section">Sec. 201. Prescription drug importation.</toc-entry> <toc-entry idref="idE1F911765C294F81AE9D5B5A0294C0A8" level="section">Sec. 202. Sense of the Senate regarding trade agreements.</toc-entry> <toc-entry idref="id474C4C3C9356481498CCF30046B5BD01" level="title">TITLE III—Medicare and Medicaid rebates</toc-entry> <toc-entry idref="HC0383052DF22480C890A37B9CF760533" level="section">Sec. 301. Requiring drug manufacturers to provide drug rebates for drugs dispensed to low-income individuals.</toc-entry> <toc-entry idref="id03B3DEE472AF4558A2C62E42D8FE4897" level="section">Sec. 302. Applying the Medicaid additional rebate requirement to generic drugs.</toc-entry> <toc-entry idref="idE8E11E83F9424286BC7875845024F1B3" level="title">TITLE IV—Pay-for-delay blocking</toc-entry> <toc-entry idref="idF27502154AC84B6DA68803A5540C7960" level="section">Sec. 401. Preserving access to affordable generics.</toc-entry> <toc-entry idref="id3CF04791970945F5B186E782BFF5CD5B" level="title">TITLE V—Fraud</toc-entry> <toc-entry idref="id949AFDF5ED7747CA94B46DFDA34D7130" level="section">Sec. 501. Conditions on award of drug exclusivity.</toc-entry> <toc-entry idref="id3F3379B03EF542939E2D3AF12CE6623D" level="title">TITLE VI—Transparency</toc-entry> <toc-entry idref="id12D875143C494B89AFA78EFC0EE44E5A" level="section">Sec. 601. Drug manufacturer reporting.</toc-entry> </toc> </subsection></section><title id="id71102C22A3BF4CBF955610D8100F47A3" style="OLC"><enum>I</enum><header>Drugs under the Medicare program</header> <section id="HA812C80A6E8442AC999967086D96D6A6"><enum>101.</enum><header>Negotiation of lower covered part D drug prices on behalf of Medicare beneficiaries</header> <subsection id="HEC1F58FD32744FFA9D1826A1203499CA"><enum>(a)</enum><header>Negotiation by Secretary</header><text>Section 1860D–11 of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395w-111">42 U.S.C. 1395w–111</external-xref>) is amended by striking subsection (i) (relating to noninterference) and inserting the following:</text>
					<quoted-block id="HA925AF3AC289463B9D4AB3797D1487FC" style="OLC">
						<subsection id="HC151D361C79C4891AFF204240CA36BFE"><enum>(i)</enum><header>Negotiation of
				Lower Drug Prices</header>
							<paragraph id="HB550ADAE5CFF411BAB6BA0ADFD7BEC55"><enum>(1)</enum><header>In
 general</header><text>Notwithstanding any other provision of law, the Secretary shall negotiate with pharmaceutical manufacturers the prices (including discounts, rebates, and other price concessions) that may be charged to PDP sponsors and MA organizations for covered part D drugs for part D eligible individuals who are enrolled under a prescription drug plan or under an MA–PD plan.</text>
							</paragraph><paragraph id="H2891009F84B94A209701EBE1F997DEA8"><enum>(2)</enum><header>No change in
				rules for formularies</header>
								<subparagraph id="H29EF1C35F05444D7963083EEF48AF266"><enum>(A)</enum><header>In
 general</header><text>Nothing in paragraph (1) shall be construed to authorize the Secretary to establish or require a particular formulary.</text>
 </subparagraph><subparagraph id="HD8C2D6B0C2894EFBB05759BA97FC77FE"><enum>(B)</enum><header>Construction</header><text>Subparagraph (A) shall not be construed as affecting the Secretary’s authority to ensure appropriate and adequate access to covered part D drugs under prescription drug plans and under MA–PD plans, including compliance of such plans with formulary requirements under section 1860D–4(b)(3).</text>
 </subparagraph></paragraph><paragraph id="HC08797AA56104DCFA669821915B4E471"><enum>(3)</enum><header>Construction</header><text>Nothing in this subsection shall be construed as preventing the sponsor of a prescription drug plan, or an organization offering an MA–PD plan, from obtaining a discount or reduction of the price for a covered part D drug below the price negotiated under paragraph (1).</text>
							</paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block>
				</subsection><subsection commented="no" display-inline="no-display-inline" id="HEEC312A3FEBA4C21A371F000743D9AAD"><enum>(b)</enum><header>Effective
 date</header><text>The amendment made by subsection (a) shall take effect on the date of the enactment of this Act and shall first apply to negotiations and prices for plan years beginning on January 1, 2016.</text>
				</subsection></section><section commented="no" display-inline="no-display-inline" id="id7123C3DFACD9454995947A1A9FCDE761"><enum>102.</enum><header>Acceleration of the closing of the Medicare Part D donut hole</header>
 <subsection id="idF39252B13A714E80AC8CEA3EB338C057"><enum>(a)</enum><header>Reduction in coinsurance</header><text>Section 1860D–2(b)(2) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395w-102">42 U.S.C. 1395w–102(b)(2)</external-xref>) is amended—</text> <paragraph id="id77026C12544B4F4C9D11AC95B3B35D96"><enum>(1)</enum><text>in each of subclauses (II) and (III) of subparagraph (C)(ii), by striking <quote>2020</quote> and inserting <quote>2017</quote>; and</text>
 </paragraph><paragraph id="idA5190B009C0542789C75D8B504E91BF7"><enum>(2)</enum><text>in subparagraph (D)(ii)—</text> <subparagraph id="id5B2C9D04198E4012801102F0C5EEB441"><enum>(A)</enum><text>in subclause (II), by inserting <quote>and</quote> at the end; and</text>
 </subparagraph><subparagraph id="idCB8377C7CEFD4E149E1EFF5F8326B46C"><enum>(B)</enum><text>by striking subclauses (III) through (VI) and inserting the following:</text> <quoted-block display-inline="no-display-inline" id="idDE219427635347C5A5F871D8F31F5E86" style="OLC"> <subclause id="id1FC1E39E0C234DF08723494FA967360E"><enum>(III)</enum><text>2017 is 100 percent.</text></subclause><after-quoted-block>.</after-quoted-block></quoted-block>
 </subparagraph></paragraph></subsection><subsection id="id8494EEAF4EA34432995CCA920B83E493"><enum>(b)</enum><header>Increase in manufacturer rebate</header><text>Section 1860D–14A(g)(4)(A) of the Social Security Act (42 U.S.C. 1395w–114a(g)(4)(A)) is amended by inserting <quote>(or, for 2017 and subsequent years, 75 percent)</quote> after <quote>50 percent</quote>.</text>
				</subsection></section></title><title id="id2A89E3CBB2EC4BDB8EA7E34D4F4902FE" style="OLC"><enum>II</enum><header>Prescription drug importation</header>
			<section commented="no" id="id94E3F8BBCD35451EA2F2FF4AC3733E9F"><enum>201.</enum><header>Prescription drug importation</header>
 <subsection commented="no" id="idBE57B6F03225485E968D510A140261EA"><enum>(a)</enum><header>Importation by pharmacists and wholesalers</header><text>Section 804(b) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/384">21 U.S.C. 384(b)</external-xref>) is amended by striking <quote>The Secretary,</quote> and inserting <quote>The Secretary, not later than January 1, 2016,</quote>.</text>
				</subsection><subsection commented="no" id="id5D67F068D01F49BA98CB87E054FB47BC"><enum>(b)</enum><header>Importation by individuals</header>
 <paragraph commented="no" id="id91F4BF2BFBC443B3A124F024DF8A7068"><enum>(1)</enum><header>In general</header><text>Section 804 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/384">21 U.S.C. 384</external-xref>) is amended—</text> <subparagraph commented="no" id="id817AC153E2084697BC7B618C27C7D951"><enum>(A)</enum><text>in subsection (f), by striking <quote>within Canada</quote>;</text>
 </subparagraph><subparagraph commented="no" id="id8CEF76D604F745D0A0F5623F7EC4F265"><enum>(B)</enum><text>in subsection (j)—</text> <clause commented="no" id="id9DD317A32196459485C387C8601BF529"><enum>(i)</enum><text>in paragraph (1), in the matter preceding subparagraph (A), by inserting <quote>from countries other than Canada</quote> after <quote>devices</quote>; and</text>
 </clause><clause commented="no" id="idBC34BF00518F48808341F7CF0EC59DA6"><enum>(ii)</enum><text>in paragraph (3)—</text> <subclause commented="no" id="id5037EA618D8544F2BC079EEDA341C176"><enum>(I)</enum><text>in the heading, by striking <quote><header-in-text level="paragraph" style="OLC">from Canada</header-in-text></quote> and inserting <quote><header-in-text level="paragraph" style="OLC">from countries other than Canada</header-in-text></quote>; and</text>
 </subclause><subclause commented="no" id="id0525261FC6194C7599BDF1CC2BB07099"><enum>(II)</enum><text>in subparagraph (C), by striking <quote>from Canada,</quote>; and</text> </subclause></clause></subparagraph><subparagraph commented="no" id="id10832FE652FE417AAE574ACEF79C0F9B"><enum>(C)</enum><text>by striking subsection (l) and inserting the following:</text>
							<quoted-block display-inline="no-display-inline" id="id30F058434B104AF9A0BD8F45BF5A30FA" style="OLC">
 <subsection id="id8A070A5409494B0DB4F7AEAA3EF5F03B"><enum>(l)</enum><header>Importation of prescription drugs from Canada</header><text>Individuals may import from Canada any prescription drug that meets the requirements of subparagraphs (A) through (F) of subsection (j)(3).</text></subsection><after-quoted-block>.</after-quoted-block></quoted-block>
 </subparagraph></paragraph><paragraph commented="no" id="id2C63BD9DB9064030BAF4E43EF13D472E"><enum>(2)</enum><header>Regulations</header><text>Not later than January 1, 2016, the Secretary of Health and Human Services shall promulgate regulations with respect to subsection (l) of section 804 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/384">21 U.S.C. 384</external-xref>) (as amended by paragraph (1)(B)).</text>
 </paragraph><paragraph commented="no" id="id3686B9B100A242CFA7F7B8ADA503EFAC"><enum>(3)</enum><header>Effective date</header><text>The amendments made by paragraph (1) shall take effect on the effective date of the final regulations promulgated in accordance with paragraph (2).</text>
 </paragraph></subsection><subsection commented="no" id="idF3CB8E95DF88487B8BD8753B417F6A98"><enum>(c)</enum><header>FDASIA amendment</header><text>Subsection (c) of section 708 of the Food and Drug Administration Safety and Innovation Act (<external-xref legal-doc="public-law" parsable-cite="pl/112/144">Public Law 112–144</external-xref>; 126 Stat. 1068) is amended by striking <quote>The amendment made by</quote> and all that follows through the period at the end and inserting <quote>The amendment made by subsection (a) and the regulations promulgated under subsection (b) shall apply beginning on the effective date of the regulations promulgated under section 804(b) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/384">21 U.S.C. 384(b)</external-xref>) and the amendments made by section 201(b) of the <short-title>Prescription Drug Affordability Act of 2015</short-title>.</quote>.</text>
 </subsection></section><section id="idE1F911765C294F81AE9D5B5A0294C0A8"><enum>202.</enum><header>Sense of the Senate regarding trade agreements</header><text display-inline="no-display-inline">It is the sense of the Senate that the United States Trade Representative should not negotiate trade agreements that would raise the prices of prescription drugs in the United States, extend the periods of market exclusivity otherwise available for prescription drugs, or remove flexibility in Federal or State law regarding pricing of prescription drugs.</text>
			</section></title><title id="id474C4C3C9356481498CCF30046B5BD01" style="OLC"><enum>III</enum><header>Medicare and Medicaid rebates</header>
			<section commented="no" display-inline="no-display-inline" id="HC0383052DF22480C890A37B9CF760533" section-type="subsequent-section"><enum>301.</enum><header>Requiring drug
			 manufacturers to provide drug rebates for drugs dispensed to low-income
			 individuals</header>
				<subsection commented="no" id="H86F381BE33DF4C8F861464E4E9229A0F"><enum>(a)</enum><header>In
 general</header><text display-inline="yes-display-inline">Section 1860D–2 of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395w-102">42 U.S.C. 1395w–102</external-xref>) is amended—</text>
 <paragraph commented="no" id="H8C77DC2CD9504E559497311D3F4571FF"><enum>(1)</enum><text>in subsection (e)(1), in the matter preceding subparagraph (A), by inserting <quote>and subsection (f)</quote> after <quote>this subsection</quote>; and</text>
 </paragraph><paragraph commented="no" id="HB52EFB1FB5DD482F82F9152DD5402BE0"><enum>(2)</enum><text>by adding at the end the following new subsection:</text>
						<quoted-block display-inline="no-display-inline" id="HB501E6ABC0D547D5AB3B0513F978D096" style="OLC">
							<subsection commented="no" id="H5A8E410861594C5B8EE1F7C1AC3BA644"><enum>(f)</enum><header>Prescription
				drug rebate agreement for rebate eligible individuals</header>
								<paragraph commented="no" display-inline="no-display-inline" id="HF15D7EF3CDA44A2698E8BA0F30D2C214"><enum>(1)</enum><header>Requirement</header>
									<subparagraph commented="no" id="H38216F8846F449A2B86BFEC2D70B2DF8"><enum>(A)</enum><header>In
 general</header><text>For plan years beginning on or after January 1, 2017, in this part, the term <term>covered part D drug</term> does not include any drug or biological product that is manufactured by a manufacturer that has not entered into and have in effect a rebate agreement described in paragraph (2).</text>
									</subparagraph><subparagraph commented="no" id="H94402FF8FD6F4E16BD1BDF1581792420"><enum>(B)</enum><header>2016 plan year
 requirement</header><text display-inline="yes-display-inline">Any drug or biological product manufactured by a manufacturer that declines to enter into a rebate agreement described in paragraph (2) for the period beginning on January 1, 2016, and ending on December 31, 2016, shall not be included as a <quote>covered part D drug</quote> for the subsequent plan year.</text>
									</subparagraph></paragraph><paragraph commented="no" id="H0BEC892645E0403B92B937803B5793B9"><enum>(2)</enum><header>Rebate
 agreement</header><text display-inline="yes-display-inline">A rebate agreement under this subsection shall require the manufacturer to provide to the Secretary a rebate for each rebate period (as defined in paragraph (6)(B)) ending after December 31, 2015, in the amount specified in paragraph (3) for any covered part D drug of the manufacturer dispensed after December 31, 2015, to any rebate eligible individual (as defined in paragraph (6)(A)) for which payment was made by a PDP sponsor or MA organization under this part for such period, including payments passed through the low-income and reinsurance subsidies under sections 1860D–14 and 1860D–15(b), respectively. Such rebate shall be paid by the manufacturer to the Secretary not later than 30 days after the date of receipt of the information described in section 1860D–12(b)(7), including as such section is applied under section 1857(f)(3), or 30 days after the receipt of information under subparagraph (D) of paragraph (3), as determined by the Secretary. Insofar as not inconsistent with this subsection, the Secretary shall establish terms and conditions of such agreement relating to compliance, penalties, and program evaluations, investigations, and audits that are similar to the terms and conditions for rebate agreements under paragraphs (3) and (4) of section 1927(b).</text>
								</paragraph><paragraph commented="no" display-inline="no-display-inline" id="HD73A1F2EEAC544CAA97A63295226021D"><enum>(3)</enum><header>Rebate for
				rebate eligible Medicare drug plan enrollees</header>
									<subparagraph commented="no" id="H420E56CD099D4A2E9D57DEEE2CDBD42F"><enum>(A)</enum><header>In
 general</header><text display-inline="yes-display-inline">The amount of the rebate specified under this paragraph for a manufacturer for a rebate period, with respect to each dosage form and strength of any covered part D drug provided by such manufacturer and dispensed to a rebate eligible individual, shall be equal to the product of—</text>
 <clause commented="no" id="H8093C10086CF4B1D9F4306874DDE5F27"><enum>(i)</enum><text display-inline="yes-display-inline">the total number of units of such dosage form and strength of the drug so provided and dispensed for which payment was made by a PDP sponsor or an MA organization under this part for the rebate period, including payments passed through the low-income and reinsurance subsidies under sections 1860D–14 and 1860D–15(b), respectively; and</text>
 </clause><clause commented="no" id="H2719EBC18BA74410848AEB7755ADFB4F"><enum>(ii)</enum><text display-inline="yes-display-inline">the amount (if any) by which—</text> <subclause commented="no" id="H74CA293666794753861340375C5CB751"><enum>(I)</enum><text>the Medicaid rebate amount (as defined in subparagraph (B)) for such form, strength, and period, exceeds</text>
 </subclause><subclause commented="no" id="HD99B9255A61F4B23B4996E82F82DB1B4"><enum>(II)</enum><text display-inline="yes-display-inline">the average Medicare drug program rebate eligible rebate amount (as defined in subparagraph (C)) for such form, strength, and period.</text>
											</subclause></clause></subparagraph><subparagraph commented="no" id="HDEEEFC5EA04D470BB7D8A63A75579879"><enum>(B)</enum><header>Medicaid rebate
 amount</header><text>For purposes of this paragraph, the term <term>Medicaid rebate amount</term> means, with respect to each dosage form and strength of a covered part D drug provided by the manufacturer for a rebate period—</text>
 <clause commented="no" id="H1CBAAEAFD8554C73AA879537529BB8B1"><enum>(i)</enum><text>in the case of a single source drug or an innovator multiple source drug, the amount specified in paragraph (1)(A)(ii)(II) or (2)(C) of section 1927(c) plus the amount, if any, specified in subparagraph (A)(ii) of paragraph (2) of such section, for such form, strength, and period; or</text>
 </clause><clause commented="no" id="HB7E70DE8FD0F4F45A989C93C7E73ED6C"><enum>(ii)</enum><text>in the case of any other covered outpatient drug, the amount specified in paragraph (3)(A)(i) of such section for such form, strength, and period.</text>
										</clause></subparagraph><subparagraph commented="no" id="HC91E341D6CCD4937A0E6EE30055FD3A8"><enum>(C)</enum><header>Average Medicare
 drug program rebate eligible rebate amount</header><text display-inline="yes-display-inline">For purposes of this subsection, the term <term>average Medicare drug program rebate eligible rebate amount</term> means, with respect to each dosage form and strength of a covered part D drug provided by a manufacturer for a rebate period, the sum, for all PDP sponsors under part D and MA organizations administering an MA–PD plan under part C, of—</text>
 <clause commented="no" id="H130CE45DF1994CA689211D831CA49309"><enum>(i)</enum><text>the product, for each such sponsor or organization, of—</text>
 <subclause commented="no" id="HBF4D2813F185475DAFC4F3E2B11084C9"><enum>(I)</enum><text display-inline="yes-display-inline">the sum of all rebates, discounts, or other price concessions (not taking into account any rebate provided under paragraph (2) or any discounts under the program under section 1860D–14A) for such dosage form and strength of the drug dispensed, calculated on a per-unit basis, but only to the extent that any such rebate, discount, or other price concession applies equally to drugs dispensed to rebate eligible Medicare drug plan enrollees and drugs dispensed to PDP and MA–PD enrollees who are not rebate eligible individuals; and</text>
 </subclause><subclause commented="no" id="HF28CC1ABAF3E4C2ABC276A1465362AD9"><enum>(II)</enum><text display-inline="yes-display-inline">the number of the units of such dosage and strength of the drug dispensed during the rebate period to rebate eligible individuals enrolled in the prescription drug plans administered by the PDP sponsor or the MA–PD plans administered by the MA organization; divided by</text>
 </subclause></clause><clause commented="no" id="HDF4A85246F294B2594E4562FFAFB6EF5"><enum>(ii)</enum><text display-inline="yes-display-inline">the total number of units of such dosage and strength of the drug dispensed during the rebate period to rebate eligible individuals enrolled in all prescription drug plans administered by PDP sponsors and all MA–PD plans administered by MA organizations.</text>
										</clause></subparagraph><subparagraph commented="no" id="HA563681C4CDA43EBB1562E72C21B12A8"><enum>(D)</enum><header>Use of
 estimates</header><text display-inline="yes-display-inline">The Secretary may establish a methodology for estimating the average Medicare drug program rebate eligible rebate amounts for each rebate period based on bid and utilization information under this part and may use these estimates as the basis for determining the rebates under this section. If the Secretary elects to estimate the average Medicare drug program rebate eligible rebate amounts, the Secretary shall establish a reconciliation process for adjusting manufacturer rebate payments not later than 3 months after the date that manufacturers receive the information collected under section 1860D–12(b)(7)(B).</text>
									</subparagraph></paragraph><paragraph commented="no" id="HD1E967730CB9409F9BB3C96B792D432B"><enum>(4)</enum><header>Length of
 agreement</header><text display-inline="yes-display-inline">The provisions of paragraph (4) of section 1927(b) (other than clauses (iv) and (v) of subparagraph (B)) shall apply to rebate agreements under this subsection in the same manner as such paragraph applies to a rebate agreement under such section.</text>
								</paragraph><paragraph commented="no" id="H4875A5A3EB604CF5B854188DDA8280DD"><enum>(5)</enum><header>Other terms and
 conditions</header><text>The Secretary shall establish other terms and conditions of the rebate agreement under this subsection, including terms and conditions related to compliance, that are consistent with this subsection.</text>
 </paragraph><paragraph commented="no" id="H6735DFFE46D441988AFAEA41FA4CA695"><enum>(6)</enum><header>Definitions</header><text>In this subsection and section 1860D–12(b)(7):</text>
									<subparagraph commented="no" id="HC95BC8CE14234E929D99F27B0E189DAB"><enum>(A)</enum><header>Rebate eligible
 individual</header><text>The term <term>rebate eligible individual</term> means—</text>
 <clause commented="no" id="H90000463F9F54DEEB06DD697E3DB20EB"><enum>(i)</enum><text display-inline="yes-display-inline">a subsidy eligible individual (as defined in section 1860D–14(a)(3)(A));</text>
 </clause><clause commented="no" id="HAD3DE21B2D1642689DC064DDA8FD3A13"><enum>(ii)</enum><text display-inline="yes-display-inline">a Medicaid beneficiary treated as a subsidy eligible individual under clause (v) of section 1860D–14(a)(3)(B); and</text>
 </clause><clause commented="no" id="H710B2BE0EA1C4B98B083A6C4EB422011"><enum>(iii)</enum><text display-inline="yes-display-inline">any part D eligible individual not described in clause (i) or (ii) who is determined for purposes of the State plan under title XIX to be eligible for medical assistance under clause (i), (iii), or (iv) of section 1902(a)(10)(E).</text>
										</clause></subparagraph><subparagraph commented="no" id="H9247DD75A3CC4FC3A18BFD41E04A2EB5"><enum>(B)</enum><header>Rebate
 period</header><text>The term <term>rebate period</term> has the meaning given such term in section 1927(k)(8).</text></subparagraph></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block>
					</paragraph></subsection><subsection commented="no" display-inline="no-display-inline" id="H71B829CD44604A5C958DE49F334F8287"><enum>(b)</enum><header>Reporting
			 requirement for the determination and payment of rebates by manufacturers
			 related To rebate for rebate eligible Medicare drug plan enrollees</header>
					<paragraph commented="no" id="HD45F56161C9247A8B1D9A4E6A807B385"><enum>(1)</enum><header>Requirements for
 PDP sponsors</header><text>Section 1860D–12(b) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395w-112">42 U.S.C. 1395w–112(b)</external-xref>) is amended by adding at the end the following new paragraph:</text>
						<quoted-block display-inline="no-display-inline" id="H412CE7EA4B5740D88EE21E928623BA13" style="OLC">
							<paragraph commented="no" id="H37A8377FE4584ED6836A36AB1AADE346"><enum>(7)</enum><header>Reporting
				requirement for the determination and payment of rebates by
			 manufacturers
				related To rebate for rebate eligible Medicare drug plan enrollees</header>
								<subparagraph commented="no" id="H93ECEE47D7B34117965CFB4973F30554"><enum>(A)</enum><header>In
 general</header><text>For purposes of the rebate under section 1860D–2(f) for contract years beginning on or after January 1, 2017, each contract entered into with a PDP sponsor under this part with respect to a prescription drug plan shall require that the sponsor comply with subparagraphs (B) and (C).</text>
								</subparagraph><subparagraph commented="no" id="HC5E2957947CB47D68F8CE5EDFEF0E022"><enum>(B)</enum><header>Report form and
 contents</header><text display-inline="yes-display-inline">Not later than a date specified by the Secretary, a PDP sponsor of a prescription drug plan under this part shall report to each manufacturer—</text>
 <clause commented="no" id="H261A91BEB6FC4F9CA0C9B8FF16F17E17"><enum>(i)</enum><text display-inline="yes-display-inline">information (by National Drug Code number) on the total number of units of each dosage, form, and strength of each drug of such manufacturer dispensed to rebate eligible Medicare drug plan enrollees under any prescription drug plan operated by the PDP sponsor during the rebate period;</text>
 </clause><clause commented="no" display-inline="no-display-inline" id="H960A27118FA147088D05445033F98DCA"><enum>(ii)</enum><text>information on the price discounts, price concessions, and rebates for such drugs for such form, strength, and period;</text>
 </clause><clause commented="no" id="H592A54AE831740F1A5751F4EDA25FEC3"><enum>(iii)</enum><text display-inline="yes-display-inline">information on the extent to which such price discounts, price concessions, and rebates apply equally to rebate eligible Medicare drug plan enrollees and PDP enrollees who are not rebate eligible Medicare drug plan enrollees; and</text>
 </clause><clause commented="no" id="H9D8373140095454B8CA592BC97E6E42B"><enum>(iv)</enum><text display-inline="yes-display-inline">any additional information that the Secretary determines is necessary to enable the Secretary to calculate the average Medicare drug program rebate eligible rebate amount (as defined in paragraph (3)(C) of such section), and to determine the amount of the rebate required under this section, for such form, strength, and period.</text>
									</clause><continuation-text commented="no" continuation-text-level="subparagraph">Such report shall be in a form
				consistent with a standard reporting format established by the
				Secretary.</continuation-text></subparagraph><subparagraph commented="no" id="HC3BE899B7CED4C7084675D62A741E2DE"><enum>(C)</enum><header>Submission to
 Secretary</header><text display-inline="yes-display-inline">Each PDP sponsor shall promptly transmit a copy of the information reported under subparagraph (B) to the Secretary for the purpose of audit oversight and evaluation.</text>
								</subparagraph><subparagraph commented="no" id="HB12164F01BD8418D934D41D4B27A4F4A"><enum>(D)</enum><header>Confidentiality
 of information</header><text display-inline="yes-display-inline">The provisions of subparagraph (D) of section 1927(b)(3), relating to confidentiality of information, shall apply to information reported by PDP sponsors under this paragraph in the same manner that such provisions apply to information disclosed by manufacturers or wholesalers under such section, except—</text>
 <clause commented="no" id="HAB82C59FAB964B86BAED803EE3D82355"><enum>(i)</enum><text>that any reference to <quote>this section</quote> in clause (i) of such subparagraph shall be treated as being a reference to this section;</text>
 </clause><clause commented="no" id="HB71C4E529FFE47E4A7621F546CC15685"><enum>(ii)</enum><text display-inline="yes-display-inline">the reference to the Director of the Congressional Budget Office in clause (iii) of such subparagraph shall be treated as including a reference to the Medicare Payment Advisory Commission; and</text>
 </clause><clause commented="no" id="HD5DC58B0F2FF42E387C80F3B7B5A4622"><enum>(iii)</enum><text display-inline="yes-display-inline">clause (iv) of such subparagraph shall not apply.</text>
 </clause></subparagraph><subparagraph commented="no" id="H53FF2E3808B84B4F8DFD23DB1412066C"><enum>(E)</enum><header>Oversight</header><text display-inline="yes-display-inline">Information reported under this paragraph may be used by the Inspector General of the Department of Health and Human Services for the statutorily authorized purposes of audit, investigation, and evaluations.</text>
								</subparagraph><subparagraph commented="no" id="H4459729CA6CC4D0CA32624C3A719710E"><enum>(F)</enum><header>Penalties for
				failure to provide timely information and provision of false
 information</header><text>In the case of a PDP sponsor—</text> <clause commented="no" id="HEBDDA0C1299D440481D771AC2E1CD965"><enum>(i)</enum><text display-inline="yes-display-inline">that fails to provide information required under subparagraph (B) on a timely basis, the sponsor is subject to a civil money penalty in the amount of $10,000 for each day in which such information has not been provided; or</text>
 </clause><clause commented="no" id="HBB307CD9A09A457EB853F4C0DFFA3AD1"><enum>(ii)</enum><text>that knowingly (as defined in section 1128A(i)) provides false information under such subparagraph, the sponsor is subject to a civil money penalty in an amount not to exceed $100,000 for each item of false information.</text>
									</clause><continuation-text commented="no" continuation-text-level="subparagraph">Such civil money penalties are in
				addition to other penalties as may be prescribed by law. The
			 provisions of
				section 1128A (other than subsections (a) and (b)) shall apply to a
			 civil money
				penalty under this subparagraph in the same manner as such
			 provisions apply to
				a penalty or proceeding under section
				1128A(a).</continuation-text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
					</paragraph><paragraph commented="no" id="HEEE05AAF5A87460A8BD7520C6ED17241"><enum>(2)</enum><header>Application to
 MA organizations</header><text>Section 1857(f)(3) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395w-27">42 U.S.C. 1395w–27(f)(3)</external-xref>) is amended by adding at the end the following:</text>
						<quoted-block display-inline="no-display-inline" id="HA8D4672ECAB6448AAC22850E18766126" style="OLC">
							<subparagraph commented="no" id="H44F5361B8BF84AADBDDF076D8CEB905B"><enum>(D)</enum><header>Reporting
				requirement related to rebate for rebate eligible Medicare drug
			 plan
 enrollees</header><text display-inline="yes-display-inline">Section 1860D–12(b)(7).</text></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block>
					</paragraph></subsection><subsection commented="no" display-inline="no-display-inline" id="HADFAC0EC1CF849F89AFA07D55EF243E6"><enum>(c)</enum><header>Deposit of
 rebates into Medicare Prescription Drug Account</header><text>Section 1860D–16(c) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395w-116">42 U.S.C. 1395w–116(c)</external-xref>) is amended by adding at the end the following new paragraph:</text>
					<quoted-block display-inline="no-display-inline" id="H0E9EE69A509042F1A87755AC0DC60A52" style="OLC">
						<paragraph commented="no" id="HB1FE305773CE4316A2CCE842D56C2FCA"><enum>(6)</enum><header>Rebate for
 rebate eligible Medicare drug plan enrollees</header><text display-inline="yes-display-inline">Amounts paid under a rebate agreement under section 1860D–2(f) shall be deposited into the Account.</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
				</subsection><subsection commented="no" display-inline="no-display-inline" id="HA29914FF3F814A779E460A290F1F6068"><enum>(d)</enum><header>Exclusion from
			 determination of best price and average manufacturer price under
			 Medicaid</header>
					<paragraph commented="no" display-inline="no-display-inline" id="H4C208629B3CE4781967560E87734CD1C"><enum>(1)</enum><header>Exclusion from
 best price determination</header><text>Section 1927(c)(1)(C)(ii)(I) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1396r-8">42 U.S.C. 1396r–8(c)(1)(C)(ii)(I)</external-xref>) is amended by inserting <quote>and amounts paid under a rebate agreement under section 1860D–2(f)</quote> after <quote>this section</quote>.</text>
					</paragraph><paragraph commented="no" display-inline="no-display-inline" id="H7FC0DA4F63AB413BB5F35037EB6DA61E"><enum>(2)</enum><header>Exclusion from
 average manufacturer price determination</header><text>Section 1927(k)(1)(B)(i) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1396r-8">42 U.S.C. 1396r–8(k)(1)(B)(i)</external-xref>) is amended—</text>
 <subparagraph commented="no" display-inline="no-display-inline" id="H5F2E251BFFF14E24ABC0865CF570716C"><enum>(A)</enum><text>in subclause (IV), by striking <quote>and</quote> after the semicolon;</text>
 </subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="HCFF33BEBBEF94391B045128A5857DC26"><enum>(B)</enum><text>in subclause (V), by striking the period at the end and inserting <quote>; and</quote>; and</text>
 </subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H49FFD0736F774EEAA1CDE9B2C70E0CE7"><enum>(C)</enum><text>by adding at the end the following:</text>
							<quoted-block display-inline="no-display-inline" id="HDEA75D6B3C7941A689580980D7B43EA3" style="OLC">
 <subclause commented="no" display-inline="no-display-inline" id="HD5A293FB58A94BCF9FBC63E7222992AC"><enum>(VI)</enum><text>amounts paid under a rebate agreement under section 1860D–2(f).</text></subclause><after-quoted-block>.</after-quoted-block></quoted-block>
						</subparagraph></paragraph></subsection></section><section commented="no" display-inline="no-display-inline" id="id03B3DEE472AF4558A2C62E42D8FE4897"><enum>302.</enum><header>Applying the Medicaid additional rebate requirement to generic drugs</header>
 <subsection id="H48972611F47B41E2A294E5BEDB40D090"><enum>(a)</enum><header>In general</header><text>Section 1927(c)(3) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1396r-8">42 U.S.C. 1396r–8(c)(3)</external-xref>) is amended—</text> <paragraph id="H3A98BBECEDE642C39837391067815E22"><enum>(1)</enum><text>in subparagraph (A), by striking <quote>The amount</quote> and inserting <quote>Except as provided in subparagraph (C), the amount</quote>; and</text>
 </paragraph><paragraph id="H9A97DDED1C67435382CE2233C0C53D7A"><enum>(2)</enum><text>by adding at the end the following new subparagraph:</text> <quoted-block display-inline="no-display-inline" id="H36F833E2DE5947F8B96EDF0D59BDE550" style="OLC"> <subparagraph id="H16342ED678FB424BA8970C3F5ECB6F73"><enum>(C)</enum><header>Additional rebate</header> <clause id="HEA2ADA099C704613A9D5273BE2480E84"><enum>(i)</enum><header>In general</header><text>The amount of the rebate specified in this paragraph for a rebate period, with respect to each dosage form and strength of a covered outpatient drug other than a single source drug or an innovator multiple source drug, shall be increased in the manner that the rebate for a dosage form and strength of a single source drug or an innovator multiple source drug is increased under subparagraphs (A) and (D) of paragraph (2), except as provided in clause (ii).</text>
 </clause><clause id="H0AAAB6BBEC53473AA0ED8B00C758B80B"><enum>(ii)</enum><header>Special rules for application of provision</header><text>In applying subparagraphs (A) and (D) of paragraph (2) under clause (i)—</text> <subclause id="HE7BF17E344BB4A4AB3CD744840CB2590"><enum>(I)</enum><text display-inline="yes-display-inline">the reference in subparagraph (A)(i) of such paragraph to <quote>1990</quote> shall be deemed a reference to <quote>2014</quote>;</text>
 </subclause><subclause id="H0CB1F8C692D541C8B58AD641749552B9"><enum>(II)</enum><text display-inline="yes-display-inline">subject to clause (iii), the reference in subparagraph (A)(ii) of such paragraph to <quote>calendar quarter beginning July 1, 1990</quote> shall be deemed a reference to the <quote>calendar quarter in which the average manufacturer price for the drug is the lowest during the 12-calendar quarter period ending on September 30, 2014</quote>;</text>
 </subclause><subclause id="HEDA52A8FF1AC4EA5B907147F9965E73E"><enum>(III)</enum><text display-inline="yes-display-inline">subject to clause (iii), the reference in subparagraph (A)(ii) of such paragraph to <quote>September 1990</quote> shall be deemed a reference to <quote>the last month of such calendar quarter</quote>;</text> </subclause><subclause id="H8587C9677CD5461D9D6584BCC4074652"><enum>(IV)</enum><text display-inline="yes-display-inline">the references in subparagraph (D) of such paragraph to <quote>paragraph (1)(A)(ii)</quote>, <quote>this paragraph</quote>, and <quote>December 31, 2009</quote> shall be deemed references to <quote>subparagraph (A)</quote>, <quote>this subparagraph</quote>, and <quote>December 31, 2014</quote>, respectively; and</text>
 </subclause><subclause id="H597AF7B25D04493EB7DF2E33DABABB3A"><enum>(V)</enum><text>any reference in such paragraph to a <quote>single source drug or an innovator multiple source drug</quote> shall be deemed to be a reference to a drug to which clause (i) applies.</text> </subclause></clause><clause id="H037237BD844144BAA4501532BB8B21DC"><enum>(iii)</enum><header>Special rule for certain noninnovator multiple source drugs</header><text display-inline="yes-display-inline">In applying paragraph (2)(A)(ii)(II) under clause (i) with respect to a covered outpatient drug that is first sold as a drug other than a single source drug or an innovator multiple source drug after the date that is 3 years before the date of the enactment of this subparagraph, such paragraph shall be applied—</text>
 <subclause id="HEA5AD541DC9149FCB9A500AE041DBC09"><enum>(I)</enum><text>by substituting <quote>the applicable quarter</quote> for <quote>the calendar quarter beginning July 1, 1990</quote>; and</text> </subclause><subclause id="H460B26EAB5ED4098A77ABD6CB412B623"><enum>(II)</enum><text>by substituting <quote>the last month in such applicable quarter</quote> for <quote>September 1990</quote>.</text>
 </subclause></clause><clause id="H5366F4D1662946F9BB20E7F254FEE6DE"><enum>(iv)</enum><header>Applicable quarter defined</header><text display-inline="yes-display-inline">In this subsection, the term <term>applicable quarter</term> means, with respect to a drug described in clause (iii), the fifth full calendar quarter in which the drug is sold as a drug other than a single source drug or an innovator multiple source drug.</text>
								</clause></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block>
 </paragraph></subsection><subsection id="H62C9B7F9A7754F7281562E6653B0D1AC"><enum>(b)</enum><header>Effective date</header><text>The amendments made by subsection (a) shall apply to rebate periods beginning after December 31, 2014.</text>
				</subsection></section></title><title id="idE8E11E83F9424286BC7875845024F1B3" style="OLC"><enum>IV</enum><header>Pay-for-delay blocking</header>
			<section id="idF27502154AC84B6DA68803A5540C7960" section-type="subsequent-section"><enum>401.</enum><header>Preserving access to affordable generics</header>
 <text display-inline="no-display-inline">The Federal Trade Commission Act (<external-xref legal-doc="usc" parsable-cite="usc/15/44">15 U.S.C. 44 et seq.</external-xref>) is amended by inserting after section 26 (<external-xref legal-doc="usc" parsable-cite="usc/15/57c-2">15 U.S.C. 57c–2</external-xref>) the following:</text>
				<quoted-block display-inline="no-display-inline" id="ida419b06e6ec748448c2c87864ecb8334" style="OLC">
					<section id="id66464B1C7BC44E3A9CA7727877FC9456"><enum>27.</enum><header>Preserving access to affordable generics</header>
						<subsection id="id1f9c5b5a6ebe4458973bb58236f58449"><enum>(a)</enum><header>In general</header>
 <paragraph id="id456760ce84554ba3981af2db37361fea"><enum>(1)</enum><header>Enforcement proceeding</header><text>The Commission may initiate a proceeding to enforce the provisions of this section against the parties to any agreement resolving or settling, on a final or interim basis, a patent infringement claim, in connection with the sale of a drug product.</text>
 </paragraph><paragraph id="id375b6e78b07d40c2a0e31a89ee2b2de1"><enum>(2)</enum><header>Presumption and violation</header><text>In such a proceeding, an agreement shall be presumed to have anticompetitive effects and be a violation of this section if—</text>
 <subparagraph id="idd9a7ba2dd37e4eca872efb642ab7f33f"><enum>(A)</enum><text>an ANDA filer receives anything of value, including an exclusive license; and</text> </subparagraph><subparagraph id="id09c15b713c08419380fb77c7483b7284"><enum>(B)</enum><text>the ANDA filer agrees to limit or forego research, development, manufacturing, marketing, or sales of the ANDA product for any period of time.</text>
 </subparagraph></paragraph></subsection><subsection id="id5e6b3637152b46c4afc3505b84271a85"><enum>(b)</enum><header>Exclusions</header><text>Nothing in this section shall prohibit a resolution or settlement of a patent infringement claim in which the consideration granted by the NDA holder to the ANDA filer as part of the resolution or settlement includes only one or more of the following:</text>
 <paragraph id="id0eab7f8af80d4dbbb065c181c5f44fb3"><enum>(1)</enum><text>The right to market the ANDA product in the United States prior to the expiration of—</text> <subparagraph id="idf4cb4139d0e54f70bac5176c668a636b"><enum>(A)</enum><text>any patent that is the basis for the patent infringement claim; or</text>
 </subparagraph><subparagraph id="id6c9ac31bf6f545ac9a69902efd5f3492"><enum>(B)</enum><text>any patent right or other statutory exclusivity that would prevent the marketing of such drug.</text> </subparagraph></paragraph><paragraph id="id0ed16d4c2b1447ef9b8af14b14237486"><enum>(2)</enum><text>A payment for reasonable litigation expenses not to exceed $7,500,000.</text>
 </paragraph><paragraph id="id5697a834e62f4f8fbd38f3dbe461ac04"><enum>(3)</enum><text>A covenant not to sue on any claim that the ANDA product infringes a United States patent.</text> </paragraph></subsection><subsection id="ida302a6989ae2447fb643c9d0153142f6"><enum>(c)</enum><header>Definitions</header><text>In this section:</text>
 <paragraph id="id75ae50e91a84433a9834faffb4d1fb47"><enum>(1)</enum><header>Agreement</header><text>The term <term>agreement</term> means anything that would constitute an agreement under section 1 of the Sherman Act (<external-xref legal-doc="usc" parsable-cite="usc/15/1">15 U.S.C. 1</external-xref>) or section 5 of this Act.</text>
 </paragraph><paragraph id="idbacdc9f94b46472cb79f8f981df3ddd0"><enum>(2)</enum><header>Agreement resolving or settling a patent infringement claim</header><text>The term <term>agreement resolving or settling a patent infringement claim</term> includes any agreement that is entered into within 30 days of the resolution or the settlement of the claim, or any other agreement that is contingent upon, provides a contingent condition for, or is otherwise related to the resolution or settlement of the claim.</text>
 </paragraph><paragraph id="id1a2edb50df9642fdb361662acf270f2b"><enum>(3)</enum><header>ANDA</header><text>The term <term>ANDA</term> means an abbreviated new drug application filed under section 505(j) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(j)</external-xref>) or a new drug application filed under section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(b)(2)</external-xref>).</text>
 </paragraph><paragraph id="idc6fb0aca67ce4a82b60897a23ad695ec"><enum>(4)</enum><header>ANDA filer</header><text>The term <term>ANDA filer</term> means a party that owns or controls an ANDA filed with the Commission of Food and Drugs or has the exclusive rights under such ANDA to distribute the ANDA product.</text>
 </paragraph><paragraph id="idc99e97004fa4409cb081219548d47cbf"><enum>(5)</enum><header>ANDA product</header><text>The term <term>ANDA product</term> means the product to be manufactured under the ANDA that is the subject of the patent infringement claim.</text>
 </paragraph><paragraph id="id1ecfacb5a59c4eb8ad96782a3407dac4"><enum>(6)</enum><header>Drug product</header><text>The term <term>drug product</term> has the meaning given such term in section 314.3(b) of title 21, Code of Federal Regulations (or any successor regulation).</text>
 </paragraph><paragraph id="id08e7214c41004e1fb8172e60682d0d98"><enum>(7)</enum><header>NDA</header><text>The term <term>NDA</term> means a new drug application filed under section 505(b) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(b)</external-xref>).</text>
 </paragraph><paragraph id="id07f5075b59b74ae399639ababc6da88e"><enum>(8)</enum><header>NDA holder</header><text>The term <term>NDA holder</term> means—</text> <subparagraph id="id3cf8f45382d346b19ffbe2bf8630f39c"><enum>(A)</enum><text>the holder of an approved NDA application for a drug product;</text>
 </subparagraph><subparagraph id="id2bd5109c972041aa810c343bf57803cd"><enum>(B)</enum><text>a person owning or controlling enforcement of the patent listed in the Approved Drug Products With Therapeutic Equivalence Evaluations (commonly known as the <quote>FDA Orange Book</quote>) in connection with the NDA; or</text>
 </subparagraph><subparagraph id="ide76ef68a819e46f0981ddd5626fcbd12"><enum>(C)</enum><text>the predecessors, subsidiaries, divisions, groups, and affiliates controlled by, controlling, or under common control with any of the entities described in subparagraphs (A) and (B) (such control to be presumed by direct or indirect share ownership of 50 percent or greater), as well as the licensees, licensors, successors, and assigns of each of the entities.</text>
 </subparagraph></paragraph><paragraph id="id834d27e96de44673bf5e6d7878b42fe9"><enum>(9)</enum><header>Party</header><text>The term <term>party</term> means any person, partnership, corporation, or other legal entity.</text> </paragraph><paragraph id="id8c559f48785f46cc98af23a4baf9f305"><enum>(10)</enum><header>Patent infringement</header><text>The term <term>patent infringement</term> means infringement of any patent or of any filed patent application, extension, reissue, renewal, division, continuation, continuation in part, reexamination, patent term restoration, patents of addition, and extensions thereof.</text>
 </paragraph><paragraph id="id1ef89b6c5082427db025fc768a88ad6e"><enum>(11)</enum><header>Patent infringement claim</header><text>The term <term>patent infringement claim</term> means any allegation made to an ANDA filer, whether or not included in a complaint filed with a court of law, that its ANDA or ANDA product may infringe any patent held by, or exclusively licensed to, the NDA holder of the drug product.</text>
 </paragraph><paragraph id="idc26dcab4782344f0bb52e6e735378a75"><enum>(12)</enum><header>Statutory exclusivity</header><text>The term <term>statutory exclusivity</term> means those prohibitions on the approval of drug applications under clauses (ii) through (iv) of section 505(c)(3)(E) (5- and 3-year data exclusivity), section 527 (orphan drug exclusivity), or section 505A (pediatric exclusivity) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(c)(3)(E)</external-xref>, 360cc, 355a).</text>
							</paragraph></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block>
			</section></title><title id="id3CF04791970945F5B186E782BFF5CD5B" style="OLC"><enum>V</enum><header>Fraud</header>
			<section id="id949AFDF5ED7747CA94B46DFDA34D7130"><enum>501.</enum><header>Conditions on
 award of drug exclusivity</header><text display-inline="no-display-inline">Subchapter E of chapter V of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360bbb">21 U.S.C. 360bbb et seq.</external-xref>) is amended by adding at the end the following:</text>
				<quoted-block display-inline="no-display-inline" id="idF4767C845B774A008D951E1B2EDD9EF8" style="OLC">
					<section commented="no" id="id37EB890AEB6C48F6974E80190B8931E0"><enum>569D.</enum><header>Conditions on
		  award of drug exclusivity</header>
						<subsection id="idFA302001B2E3445783F82D9183E631A9"><enum>(a)</enum><header>Termination of
 exclusivity</header><text>Notwithstanding any other provision of this Act, any period of exclusivity described in subsection (b) granted to a person or assigned to a person on or after the date of enactment of this section with respect to a drug shall be terminated if the person to which such exclusivity was granted or any person to which such exclusivity is assigned—</text>
 <paragraph id="idCEE62B527C79433D91A6E7783FF3CEA0"><enum>(1)</enum><text>commits a violation described in subsection (c)(1) with respect to such drug; or</text>
 </paragraph><paragraph id="id9053A37BA97648CC918E25D212334451"><enum>(2)</enum><text>fails to report such a violation as required by subsection (e).</text>
							</paragraph></subsection><subsection id="id8B93DA28FFD84E4D92377CBDF82D2173"><enum>(b)</enum><header>Exclusivities
 affected</header><text>The periods of exclusivity described in this subsection are those periods of exclusivity granted under any of the following sections:</text>
 <paragraph id="id8D8999420D804CCABD49B643DA300FDD"><enum>(1)</enum><text>Clause (ii), (iii), or (iv) of section 505(c)(3)(E).</text>
 </paragraph><paragraph id="idD319A523233F4DD591EC8F4593D322A1"><enum>(2)</enum><text>Clause (iv) of section 505(j)(5)(B).</text>
 </paragraph><paragraph id="id264551B1EFE24947808CDBD882123B43"><enum>(3)</enum><text>Clause (ii), (iii), or (iv) of section 505(j)(5)(F).</text>
 </paragraph><paragraph id="id48D64B872AD246799D653C5D1A6DDAAC"><enum>(4)</enum><text>Section 505A.</text>
 </paragraph><paragraph id="id45654F99E00840E896354329254B97E1"><enum>(5)</enum><text>Section 505E.</text>
 </paragraph><paragraph id="idB0F0C013EAB0418CA70704F292B8123B"><enum>(6)</enum><text>Section 527.</text>
 </paragraph><paragraph id="idDC89F304D11140FE90E32E519E266C5A"><enum>(7)</enum><text>Section 351(k)(7) of the Public Health Service Act.</text>
 </paragraph><paragraph id="id5108B26EF4B147F7832F2AD97DEC812A"><enum>(8)</enum><text>Any other provision of this Act that provides for market exclusivity (or extension of market exclusivity) with respect to a drug.</text>
							</paragraph></subsection><subsection id="id9506EE8F7FCC4C07855D84D57A55377C"><enum>(c)</enum><header>Violations</header>
							<paragraph id="id872F5F6035894610BDC5E4BC62BDAE57"><enum>(1)</enum><header>In
 general</header><text>A violation described in this subsection is a violation of a law described in paragraph (2) that results in—</text>
 <subparagraph id="idF37764E1847E4851A8B72E23F68A13A0"><enum>(A)</enum><text>a criminal conviction of a person described in subsection (a);</text>
 </subparagraph><subparagraph id="id37431B019E074FD0AF2D8F08D13CE41A"><enum>(B)</enum><text>a civil judgment against a person described in subsection (a); or</text>
 </subparagraph><subparagraph id="idB6FFE5FD19C14CCCBF6FEBCD50AEDF1B"><enum>(C)</enum><text>a settlement agreement in which a person described in subsection (a) admits to fault.</text>
								</subparagraph></paragraph><paragraph id="id20672CD5C1BE453E8A4B9941E02BD301"><enum>(2)</enum><header>Laws
 described</header><text>The laws described in this paragraph are the following:</text>
 <subparagraph id="id59537301EAC34AFDAFC7B0CDCAD0ABB6"><enum>(A)</enum><text>The provisions of this Act that prohibit—</text>
 <clause id="id0D0FBEA5B8A344888F45691424401D18"><enum>(i)</enum><text>the adulteration or misbranding of a drug;</text>
 </clause><clause id="id963EA34F7E0A4A9EAFAA5FAEFDFC9995"><enum>(ii)</enum><text>the making of false statements to the Secretary or committing fraud; or</text>
 </clause><clause id="idC037DC6E749446FFAB6761E6A66193FC"><enum>(iii)</enum><text>the illegal marketing of a drug.</text>
 </clause></subparagraph><subparagraph id="id5070CE9EA95C471C931B7A13283BAB0B"><enum>(B)</enum><text>The provisions of subchapter III of <external-xref legal-doc="usc-chapter" parsable-cite="usc-chapter/31/37">chapter 37</external-xref> of title 31, United States Code (commonly known as the <quote>False Claims Act</quote>).</text>
 </subparagraph><subparagraph id="idBF81290B5D344220BE10B56EFA159657"><enum>(C)</enum><text>Section 287 of title 18, United States Code.</text>
 </subparagraph><subparagraph id="idd4bd18de79914b089b2f16499da87f3e"><enum>(D)</enum><text>The Medicare and Medicaid Patient Protection and Program Act of 1987 (commonly known as the <quote>Antikickback Statute</quote>).</text>
 </subparagraph><subparagraph id="idADA94603CA4E49E9917F3EF8E4D48DDF"><enum>(E)</enum><text>Section 1927 of the Social Security Act.</text>
 </subparagraph><subparagraph id="id94FB49FE47D249A8BD9C093B1AEF860C"><enum>(F)</enum><text>A State law against fraud comparable to a law described in subparagraphs (A) through (E).</text>
								</subparagraph></paragraph></subsection><subsection id="id2463A60C54804713A57FA531E183C9BD"><enum>(d)</enum><header>Date of
 exclusivity termination</header><text>The date on which the exclusivity shall be terminated as described in subsection (a) is the date on which, as applicable—</text>
 <paragraph id="id7A192F8866AF4D668C933D74BE1E1997"><enum>(1)</enum><text>a final judgment is entered relating to a violation described in subparagraph (A) or (B) of subsection (c)(1); or</text>
 </paragraph><paragraph id="id88BE6622A9ED4D66A6A1C6C60D2DF382"><enum>(2)</enum><subparagraph commented="no" display-inline="yes-display-inline" id="id9E6242A8B30C4A31AD16551879786C94"><enum>(A)</enum><text>a settlement agreement described in subsection (c)(1)(C) is approved by a court order that is or becomes final and nonappealable; or</text>
 </subparagraph><subparagraph id="id5064D1205EC44B1883B6B3D15D65FAD1" indent="up1"><enum>(B)</enum><text>if there is no court order approving a settlement agreement described in subsection (c)(1)(C), a court order dismissing the applicable case, issued after the settlement agreement, is or becomes final and nonappealable.</text>
								</subparagraph></paragraph></subsection><subsection id="idEF769892AA864FA88303595A35284BF1"><enum>(e)</enum><header>Reporting of
 information</header><text>A person described in subsection (a) that commits a violation described in subsection (c)(1) shall report such violation to the Secretary no later than 30 days after the date that—</text>
 <paragraph id="idD98F15738127403B9A5C4DB073900ABE"><enum>(1)</enum><text>a final judgment is entered relating to a violation described in subparagraph (A) or (B) of subsection (c)(1); or</text>
 </paragraph><paragraph commented="no" display-inline="no-display-inline" id="id09F59860C5F24255AD90E199EBBE62C4"><enum>(2)</enum><subparagraph commented="no" display-inline="yes-display-inline" id="idF630F14E0D114D9BB924285224BEE4D8"><enum>(A)</enum><text>a settlement agreement described in subsection (c)(1)(C) is approved by a court order that is or becomes final and nonappealable; or</text>
 </subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id3F788B9024AF4249B9BF987AA661A9A3" indent="up1"><enum>(B)</enum><text>if there is no court order approving a settlement agreement described in subsection (c)(1)(C), a court order dismissing the applicable case, issued after the settlement agreement, is or becomes final and nonappealable.</text>
								</subparagraph></paragraph></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block>
			</section></title><title id="id3F3379B03EF542939E2D3AF12CE6623D" style="OLC"><enum>VI</enum><header>Transparency</header>
			<section id="id12D875143C494B89AFA78EFC0EE44E5A"><enum>601.</enum><header>Drug manufacturer reporting</header>
 <subsection id="idFEA24D09BFDB4BB0931FAC407D135E10"><enum>(a)</enum><header>Reporting on domestic sales</header><text display-inline="yes-display-inline">The manufacturer of a drug approved under section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>) or section 351 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262</external-xref>) shall submit to the Secretary of Health and Human Services and to Congress an annual report, which shall be made publicly available, outlining with respect to each such drug, during the previous calendar year—</text>
 <paragraph id="id206E5701E16F4E678F3891E7A7510045"><enum>(1)</enum><text>the total expenditures of the manufacturer on—</text> <subparagraph id="id8A06CCB5831B4C169877CDF0FC5FC855"><enum>(A)</enum><text>drug research and development;</text>
 </subparagraph><subparagraph id="idBD31A078D5AC4A04B337FCCE7FEF11B2"><enum>(B)</enum><text>clinical trials;</text> </subparagraph><subparagraph id="id3E37E7559CE147B4B90F6D221C501337"><enum>(C)</enum><text>materials and manufacturing;</text>
 </subparagraph><subparagraph id="id4E7236073E9A4E19839E7BD086411C8C"><enum>(D)</enum><text>acquisition costs, including costs for the purchase of patents and licensing; and</text> </subparagraph><subparagraph id="idD1EEC747D0D648EFAB8D9B2BEEAA0B8C"><enum>(E)</enum><text>marketing and advertising for the promotion of the drug to consumers and prescribers;</text>
 </subparagraph></paragraph><paragraph id="idA5815D7289144377B6CA505EB24CB8FD"><enum>(2)</enum><text>the total profit to the manufacturer attributable to such drug;</text> </paragraph><paragraph id="idC41D4DE138DD421BA993B6643312DD48"><enum>(3)</enum><text>total amount of financial assistance the manufacturer has provided through patient prescription assistance programs with respect to such drug, if any;</text>
 </paragraph><paragraph id="id2D5A66A3E7E046A1BC03C7B69EAF61B9"><enum>(4)</enum><text>any Federal benefits received by the manufacturer, including tax credits, grants from the National Institutes of Health, and other Federal benefits with respect to such drug; and</text>
 </paragraph><paragraph id="idA82361D540E140DBB8F1BD98CEA3EBF2"><enum>(5)</enum><text>any additional information the manufacturer chooses to provide related to drug pricing decisions, such as total expenditures on drug research and development or clinical trials on drugs that failed to receive approval by the Food and Drug Administration.</text>
 </paragraph></subsection><subsection id="id665B75797E35421695A68FC5FEE7E9F5"><enum>(b)</enum><header>Reporting on foreign sales</header><text>In the case of a manufacturer of a drug that sells such drug to the Federal Government, including through the health programs of the Department of Veterans Affairs, the Department of Defense, and the Indian Health Service and through the Medicare program under title XVIII of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395">42 U.S.C. 1395 et seq.</external-xref>), or that has entered into an agreement under section 340B of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/256b">42 U.S.C. 256b</external-xref>), the manufacturer shall include in the report submitted under subsection (a) information about the price of the drug, and profits from and volume of sales of the drug, in each foreign country in which the drug is sold, as applicable.</text>
				</subsection></section></title></legis-body>
</bill>


